Australia's largest stock trading and investment forum Australia's #1 stock forum

ADO

Click for more information

0.00%

2.1¢ anteotech ltd

Ann: Notice of Annual General Meeting/Proxy Form, page-21

First 21 Last

Share
Profile

Follow
rogues

767 Posts.

139

18/10/18

12:45

Post #: 36171569
Share

Originally posted by semi retired: ↑

Thank you Peter Fred , I always enjoy reading your posts , I think Mat has been effectively muzzled by the non disclosure duties that go with being a director of a company , I miss Matt's detailed research , I wish he could tell share holders about the value of ANTEO when it 16 x the benefit of sensitivity over current market bench mark , Disruptive ? YES , question is how long will it take to disrupt ?, not if .

During the year Planet Innovation (“PI” announced that their PoC diagnostic test system showed a 10-16X benefit in sensitivity over a current on-market benchmark. PI's integrated diagnostic system uses AnteoBindTM conjugates in conjunction with PI's novel reader and cartridge technology, PI patented membrane technology and also features design inputs from additional collaborators. The excellent technical results led the Company to conclude that AnteoBindTM provides commercial benefits to the Lateral Flow market. During the year and up to the date of this report a representative mix of assays including Infectious Disease, Fertility and Cardiac Care were chosen to highlight performance improvement across a range of diagnostically important segments. In addition, several particle types were selected from different manufacturers to assess AnteoBindTM compatibility across a range of supplier platforms. The objective of developing these prototype stage assays was to build a comprehensive package of validation data that would clearly highlight the improvements AnteoBindTM can deliver if incorporated in fully commercialized Lateral Flow assays. It is was also opportunity to highlight the value of AnteoBindTM activated particles as a viable input component in the development of PoC Lateral Flow assay kits. The data validation pack that was produced, using AnteoBindTM, demonstrated:
• Significant gains in limit of detection performance across all tests with better analytical sensitivity & lower limit of detection.
• Improved reproducibility of conjugate manufacturing which simplifies production and increases reliability and consistency of the test.
• Quicker test reaction time and potentially reduced sample size. • Ability to assist with faster commercialisation of opportunities allowing companies to react quickly to changes in demand and respond to pandemic disease situations.

Expand

SR, I too mirror PeterFred’s observations that are well expressed.
Whereas Management have conveyed that although 3rd party evaluations indicate Anteo have demonstrated battery performance, there is still fine tuning required to then be tested again. Now we wee an end user is sharing the testing programme. In the event of all satisfied, ramping up of an agreement would be beneficial to all.
in the POC arena, I believe the years of research provide deep resources of information and there is little development required. Kits for evaluation that feature all the attributes you highlight are available and we are informed there is a market gamechange driving Pharma in all regions. Asia was mentioned as extremely interested.
Recent articles mention Samsung developing diagnostic features within mobile phones
now seeking diagnostic technology.
I’m very happy to have the current team taking care of the exciting prospects, -they have my votes!

Originally posted by semi retired: ↑

Thank you Peter Fred , I always enjoy reading your posts , I think Mat has been effectively muzzled by the non disclosure duties that go with being a director of a company , I miss Matt's detailed research , I wish he could tell share holders about the value of ANTEO when it 16 x the benefit of sensitivity over current market bench mark , Disruptive ? YES , question is how long will it take to disrupt ?, not if .

During the year Planet Innovation (“PI” announced that their PoC diagnostic test system showed a 10-16X benefit in sensitivity over a current on-market benchmark. PI's integrated diagnostic system uses AnteoBindTM conjugates in conjunction with PI's novel reader and cartridge technology, PI patented membrane technology and also features design inputs from additional collaborators. The excellent technical results led the Company to conclude that AnteoBindTM provides commercial benefits to the Lateral Flow market. During the year and up to the date of this report a representative mix of assays including Infectious Disease, Fertility and Cardiac Care were chosen to highlight performance improvement across a range of diagnostically important segments. In addition, several particle types were selected from different manufacturers to assess AnteoBindTM compatibility across a range of supplier platforms. The objective of developing these prototype stage assays was to build a comprehensive package of validation data that would clearly highlight the improvements AnteoBindTM can deliver if incorporated in fully commercialized Lateral Flow assays. It is was also opportunity to highlight the value of AnteoBindTM activated particles as a viable input component in the development of PoC Lateral Flow assay kits. The data validation pack that was produced, using AnteoBindTM, demonstrated:
• Significant gains in limit of detection performance across all tests with better analytical sensitivity & lower limit of detection.
• Improved reproducibility of conjugate manufacturing which simplifies production and increases reliability and consistency of the test.
• Quicker test reaction time and potentially reduced sample size. • Ability to assist with faster commercialisation of opportunities allowing companies to react quickly to changes in demand and respond to pandemic disease situations.

Expand

Originally posted by semi retired: ↑

Thank you Peter Fred , I always enjoy reading your posts , I think Mat has been effectively muzzled by the non disclosure duties that go with being a director of a company , I miss Matt's detailed research , I wish he could tell share holders about the value of ANTEO when it 16 x the benefit of sensitivity over current market bench mark , Disruptive ? YES , question is how long will it take to disrupt ?, not if .

During the year Planet Innovation (“PI” announced that their PoC diagnostic test system showed a 10-16X benefit in sensitivity over a current on-market benchmark. PI's integrated diagnostic system uses AnteoBindTM conjugates in conjunction with PI's novel reader and cartridge technology, PI patented membrane technology and also features design inputs from additional collaborators. The excellent technical results led the Company to conclude that AnteoBindTM provides commercial benefits to the Lateral Flow market. During the year and up to the date of this report a representative mix of assays including Infectious Disease, Fertility and Cardiac Care were chosen to highlight performance improvement across a range of diagnostically important segments. In addition, several particle types were selected from different manufacturers to assess AnteoBindTM compatibility across a range of supplier platforms. The objective of developing these prototype stage assays was to build a comprehensive package of validation data that would clearly highlight the improvements AnteoBindTM can deliver if incorporated in fully commercialized Lateral Flow assays. It is was also opportunity to highlight the value of AnteoBindTM activated particles as a viable input component in the development of PoC Lateral Flow assay kits. The data validation pack that was produced, using AnteoBindTM, demonstrated:
• Significant gains in limit of detection performance across all tests with better analytical sensitivity & lower limit of detection.
• Improved reproducibility of conjugate manufacturing which simplifies production and increases reliability and consistency of the test.
• Quicker test reaction time and potentially reduced sample size. • Ability to assist with faster commercialisation of opportunities allowing companies to react quickly to changes in demand and respond to pandemic disease situations.

Expand

ADO Price at posting: 1.4¢ Sentiment: Buy Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

STP

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

SGP

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

There are more pages in this discussion • 6 more messages in this thread...

First 21 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.1¢		Change 0.000(0.00%)		Mkt cap ! $54.77M

Open	High	Low	Value	Volume
2.1¢	2.2¢	2.1¢	$83.79K	3.987M

Buyers (Bids)

No.	Vol.	Price($)
14	2097105	2.0¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	209711	3

View Market Depth

No.	Vol.	Price($)
1	100045	0.017
12	5392623	0.016
6	1570373	0.015
5	1270000	0.014
2	1045000	0.013

Price($)	Vol.	No.
0.018	165394	4
0.019	555555	1
0.020	469389	4
0.021	105917	1
0.022	1013156	4

Last trade - 16.10pm 19/11/2024 (20 minute delay)

ADO (ASX) Chart